HSP90
- [1]. Young JC, et al. Hsp90: a specialized but essential protein-folding tool. J Cell Biol. 2001 Jul 23;154(2):267-73. [Content Brief]
- [2]. Karagöz GE, et al. Hsp90 interaction with clients. Trends Biochem Sci. 2015 Feb;40(2):117-25. [Content Brief]
- [3]. Ausili A. Despite their structural similarities, et al. Despite their structural similarities, the cytosolic isoforms of human Hsp90 show different behaviour in thermal unfolding due to their conformation: An FTIR study. Arch Biochem Biophys. 2023 May 15;740:109599. [Content Brief]
- [4]. Assimon VA, et al. Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation. Biochemistry. 2015 Dec 8;54(48):7120-31. [Content Brief]
- [5]. Albakova Z. HSP90 multi-functionality in cancer. Front Immunol. 2024 Aug 1;15:1436973. doi: 10.3389/fimmu.2024.1436973. PMID: 39148727; PMCID: PMC11324539. et al. HSP90 multi-functionality in cancer. Front Immunol. 2024 Aug 1;15:1436973. [Content Brief]
- [6]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
- [7]. Chang C, et al. The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep. Cells. 2023 Jan 11;12(2):277. [Content Brief]
- [8]. Sims JD, et al. Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One. 2011 Apr 14;6(4):e18848. [Content Brief]
- [9]. Donnelly BF, et al. Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis. J Biol Chem. 2013 May 3;288(18):13124-35. [Content Brief]
- [10]. Chen B, et al. Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms. BMC Genomics. 2006 Jun 17;7:156. [Content Brief]
- [11]. Chaudhury S, et al. The Hsp90β Isoform: An Attractive Target for Drug Development. Med Res Rev. 2025 Sep;45(5):1452-1465. [Content Brief]
- [12]. El-Kasaby A, et al. A cytosolic relay of heat shock proteins HSP70-1A and HSP90β monitors the folding trajectory of the serotonin transporter. J Biol Chem. 2014 Oct 17;289(42):28987-9000. [Content Brief]
- [13]. Morishima Y, et al. The hsp90 cochaperone p23 is the limiting component of the multiprotein hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein: hsp90 complex. J Biol Chem. 2003 Dec 5;278(49):48754-63. [Content Brief]
- [14]. Vogt M, et al. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells. Cell Death Dis. 2023 Dec 6;14(12):799. [Content Brief]
-
HSP90 Related Products (150)
Related Products (150)
-
Antibodies (2)
-
SST0116CL1 free base
0 ImagesCat. No.: HY-164399ACAS No.: 1202920-93-1SST0116CL1 free base is a HSP90 inhibitor (IC50: 0.21 μM). SST0116CL1 free base binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 free base induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM). SST0116CL1 free base has antiproliferative activity and inhibits tumor growth. SST0116CL1 free base has antiproliferative activity and inhibits tumor growth. SST0116CL1 free base can be used for the study of leukemia, gastric and ovarian carcinoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MAO A/HSP90-IN-1
0 ImagesCat. No.: HY-155577CAS No.: 2927489-95-8MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC50 value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
HSP90-IN-29
0 ImagesCat. No.: HY-113574CAS No.: 1012788-65-6HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective HSP-90 inhibitor with an IC50 value of 30 nM. HSP90-IN-29 has antitumor activity. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
NSC145366 monohydrochloride
0 ImagesCat. No.: HY-117192CAS No.: 1052515-37-3 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
STA-1474 sodium
0 ImagesCat. No.: HY-13752BCAS No.: 1402907-09-8STA-1474 sodium is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 sodium disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 sodium inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 sodium induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 sodium induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 sodium can be used in the research of osteosarcoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CYP51/Hsp90-IN-1
0 ImagesCat. No.: HY-170816CYP51/Hsp90-IN-1 (Compound MM4) is a dual CYP51/Hsp90 inhibitor. CYP51/Hsp90-IN-1 shows antifungal activity against Candida albicans and effectively inhibits important fungal virulence factors. CYP51/Hsp90-IN-1 is promising for research of invasive candidiasis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ML189
0 ImagesCat. No.: HY-127179CAS No.: 337328-21-9ML189 is an HSP90 inhibitor. ML189 can be used in the research of infectious diseases such as candidiasis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
WK88-1
0 ImagesCat. No.: HY-164548CAS No.: 958888-32-9WK88-1 is an apoptosis inducer and Hsp90 client protein inhibitor with antiproliferative and immunomodulatory activities. WK88-1 inhibits signaling pathways such as PI3K/Akt and NF-κB, and induces mitochondrial dysfunction and cell cycle arrest. WK88-1 effectively suppresses cancer cell migration and invasion, and reverses various EGFR mutations and resistance to Gefitinib (HY-50895). WK88-1 also regulates the differentiation of monocytes and dendritic cells, blocks the expression of multiple chemokines, inhibits immune cell migration and M1 marker transcription, and restores impaired endocytic activity. WK88-1 has been used in studies of breast cancer, non-small cell lung cancer with various EGFR mutations or Met amplification, and atherosclerosis and other related diseases. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ML229
0 ImagesCat. No.: HY-127183CAS No.: 898918-58-6ML229 is an HSP90 inhibitor. ML229 can be used in the research of infectious diseases such as candidiasis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Retaspimycin
0 ImagesCat. No.: HY-15263CAS No.: 857402-23-4 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
-
0 ImagesCat. No.:Synonyms:-
Host:
-
Application:
Human,
-
Isotype:
-
Reactivity:
,
-
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -